Follow us on social media :
See More Announcements & Events
A new study by researchers shows that releasing patients the same day of a percutaneous coronary intervention versus the next day did not have any negative impacts on the patient.
The introduction of infliximab, the first biologic therapy approved for the treatment of IBD, did not result in lower rates of hospitalizations or intestinal surgeries among patients living with IBD.
There were over 145,000 naloxone kits distributed across Ontario between July 2017 and June 2018. This is approximately one naloxone kit for every 100 Ontarians, according to a new report.
See More News Releases
See More ICES News Coverage
© 2019 ICES